ACROBiosystems

South San Francisco – October 19, 2026 -- ACROBiosystems unveiled a 4-day sequence-to-affinity screening service, CHO-DirectTM, at its ACRO Innovation Day x AI on October 13, 2026, targeting the experimental validation bottleneck in AI-driven biologics discovery. The service closes the wet-lab loop in as few as 7 days when combined with developability and characterization work.

CEO Mike Chen told attendees at The Hangar that the company's customer base has grown to 13,000. He cited rising investor interest in AI-driven drug discovery as the backdrop for the event, which followed sessions in Zurich, Shanghai (May) and a September launch event.

San Diego – September 25, 2026 -- ACROBiosystems has launched CHO-Direct, a rapid high-throughput affinity validation service that delivers antibody affinity data in as little as four days from sequence submission, alongside a broader infrastructure platform called ACRO AIx aimed at AI-driven drug discovery (AIDD).

CHO-Direct compresses antibody validation timelines to four days

Using an optimized CHO cell system, CHO-Direct converts computationally generated antibody sequences into structured affinity data within days, addressing a bottleneck where AI tools generate candidate sequences faster than labs can validate them. The service leverages the protein-folding and post-translational modification environment of mammalian cells while maintaining compatibility with CHO systems already used in downstream development and manufacturing.

Zurich – September 20, 2026 -- ACROBiosystems has established a dedicated office within The HIVE Innovation Center on Campus Grand Parc in Villejuif, deepening its footprint in France's oncology research corridor. The move, facilitated by real estate operator Kadans Science Partner, gives the roughly 1,000-employee biotechnology group direct proximity to biotechs, hospitals, and translational research institutes clustered around Paris-Saclay.

ACROBiosystems joins a biocluster it entered as a member last year

The company became a member of the Paris-Saclay Cancer Cluster (PSCC) in 2025, and the new HIVE office is positioned to extend those regional ties. Campus Grand Parc concentrates oncology-focused clinical partners and research teams, an environment ACROBiosystems says aligns with its role supplying reagents and services across the drug development chain -- from recombinant proteins and antibodies to GMP-grade custom production.